Regeneron gains on 3Q12 results, Eylea guidance

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gained $9.70 to $162.69 on Wednesday after reporting the third full quarter

Read the full 162 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE